Therapy Areas: Allergy
Biopharmaceutical company BioVaxys partner SpayVac for Wildlife scales up vaccine production in Madison facility
20 November 2024 - Biopharmaceutical company BioVaxys Technology Corp (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) and SpayVac for Wildlife Inc, a developer of humane fertility-control vaccines for animals, ...
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
17 October 2024 - Clinical-stage biotechnology company IgGenix Inc announced on Wednesday that the first patient has been dosed in its ACCELERATE Peanut Phase 1 clinical trial of IGNX001, a novel ther...
ALK secures U.S. FDA approval for AccuTest Allergy Skin Testing Devices
7 October 2024 - ALK (ALKB/ OMX: ALK B / AKABY / AKBLF), a Denmark based provider of allergy prevention, diagnosis and treatment, announced on Monday that it has received U.S. FDA approval for its new...
IgGenix presents IGNX001 data at 2024 ASCIA
3 September 2024 - IgGenix Inc, a US-based preclinical antibody discovery and development company, announced on Monday that it has presented data on its lead candidate, IGNX001, an IgG4 monoclonal ant...
EURneffy approved in EU for needle-free anaphylaxis treatment
26 August 2024 - Biopharmaceutical company ARS Pharmaceuticals Inc (Nasdaq:SPRY) announced on Monday that the European Commission has approved EURneffy (adrenaline nasal spray) for the emergency treat...
Anivive Lifesciences receives new contract from National Institute of Allergy and Infectious Diseases
5 August 2024 - California-based pet pharmaceutical company at the intersection of biotech, AI, software, and veterinary medicine Anivive Lifesciences Inc announced on Friday that it has received a ne...